BAMCO Inc
RVNC

BAMCO Inc’s Revance Therapeutics, Inc. RVNC Stock Holding History

BAMCO Inc’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,023,663
Closed -$2.63M – 346
2024
Q2 		$2.63M Hold
1,023,663
– – 0.01% 282
2024
Q1 		$5.04M Hold
1,023,663
– – 0.01% 268
2023
Q4 		$9M Buy
1,023,663
+3,429
+0.3% +$28.1K 0.02% 241
2023
Q3 		$11.7M Sell
1,020,234
-102,432
-9% -$1.97M 0.03% 228
2023
Q2 		$28.4M Buy
1,122,666
+53,183
+5% +$1.66M 0.08% 173
2023
Q1 		$34.4M Sell
1,069,483
-188,225
-15% -$5.87M 0.1% 153
2022
Q4 		$23.2M Sell
1,257,708
-462,800
-27% -$10.6M 0.08% 170
2022
Q3 		$46.5M Buy
1,720,508
+37,500
+2% +$761K 0.15% 118
2022
Q2 		$23.3M Buy
1,683,008
+290,600
+21% +$4.47M 0.07% 191
2022
Q1 		$27.2M Hold
1,392,408
– – 0.07% 200
2021
Q4 		$22.7M Hold
1,392,408
– – 0.05% 250
2021
Q3 		$38.8M Buy
1,392,408
+258,476
+23% +$7.38M 0.09% 199
2021
Q2 		$33.6M Buy
1,133,932
+42,200
+4% +$1.22M 0.08% 198
2021
Q1 		$30.5M Buy
1,091,732
+350,000
+47% +$9.68M 0.08% 187
2020
Q4 		$21M Buy
741,732
+160,000
+28% +$4.14M 0.05% 212
2020
Q3 		$14.6M Hold
581,732
– – 0.04% 214
2020
Q2 		$14.2M Buy
581,732
+75,000
+15% +$1.48M 0.05% 196
2020
Q1 		$7.5M Sell
506,732
-321,000
-39% -$6.64M 0.04% 210
2019
Q4 		$13.4M Hold
827,732
– – 0.05% 193
2019
Q3 		$10.8M Buy
827,732
+192,532
+30% +$2.36M 0.04% 200
2019
Q2 		$8.24M Buy
635,200
+126,000
+25% +$1.59M 0.03% 233
2019
Q1 		$8.03M Buy
+509,200
New +$8.83M 0.03% 220
2015
Q2 		– Sell
-30,000
Closed -$622K – 365
2015
Q1 		$622K Sell
30,000
-13,000
-30% -$225K ﹤0.01% 344
2014
Q4 		$728K Hold
43,000
– – ﹤0.01% 334
2014
Q3 		$831K Buy
43,000
+23,000
+115% +$599K ﹤0.01% 330
2014
Q2 		$680K Buy
20,000
+2,500
+14% +$78.3K ﹤0.01% 320
2014
Q1 		$551K Buy
+17,500
New +$547K ﹤0.01% 328

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

BAMCO Inc's RVNC Position: Q3 2024 in Review

BAMCO Inc sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 1,023,663 shares — an estimated $2.63M sold.

BAMCO Inc first reported a position in RVNC in Q1 2014 and held it in 27 quarters. The position peaked at $46.5M in Q3 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • BAMCO Inc reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • BAMCO Inc sold 1,023,663 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $2.63M.
  • BAMCO Inc first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 27 quarters.
  • BAMCO Inc's Revance Therapeutics, Inc. position peaked at $46.5M in Q3 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on BAMCO Inc's 13F filing for Q3 2024, filed 14 Nov 2024.